PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

31 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
1.
Addin, N.S. et al.: Association of serum magnesium with metabolic syndrome and the role of chronic kidney disease: A population-based cohort study with Mendelian randomization. Diabetes Obes. Metab. 26, 1808-1820 (2024)
2.
Forst, T.* et al.: The role of incretin receptor agonists in the treatment of obesity. Diabetes Obes. Metab., DOI: 10.1111/dom.15796 (2024)
3.
Kersten, A.* et al.: The Obese Taste Bud study: Objectives and study design. Diabetes Obes. Metab. 26, 2054-2068 (2024)
4.
Lehmann, S.* et al.: Visceral fat mass dynamics in a 2-year randomized STrength versus ENdurance training trial in people with obesity. Diabetes Obes. Metab., DOI: 10.1111/dom.15767 (2024)
5.
Neeland, I.J.* ; Linge, J.* & Birkenfeld, A.L.: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes. Metab., DOI: 10.1111/dom.15728 (2024)
6.
Perakakis, N. et al.: Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes. Metab. 26, 191-200 (2024)
7.
Tanday, N. ; Tarasov, A.I.* ; Moffett, R.C.* ; Flatt, P.R.* & Irwin, N.*: Pancreatic islet cell plasticity: Pathogenic or therapeutically exploitable? Diabetes Obes. Metab. 26, 16-31 (2024)
8.
Blüher, M. ; Malhotra, A.* & Bader, G.D.*: β-cell function in treatment-naïve patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials. Diabetes Obes. Metab. 25, 1403-1407 (2023)
9.
Blüher, M. et al.: New insights into the treatment of obesity. Diabetes Obes. Metab. 25, 2058-2072 (2023)
10.
McGill, J.B.* et al.: Effects of finerenone in persons with CKD and T2D are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes. Metab. 25, 1512-1522 (2023)
11.
Schultes, B.* ; Ernst, B.* ; Hallschmid, M. ; Bueter, M.* & Meyhöfer, S.M.*: The ‘Behavioral Balance Model’: A new perspective on the aetiology and therapy of obesity. Diabetes Obes. Metab. 25, 3444-3452 (2023)
12.
Wagner, L. et al.: Brain insulin responsiveness is linked to age and peripheral insulin sensitivity. Diabetes Obes. Metab. 25, 2171-2180 (2023)
13.
Hummel, J. et al.: Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes. Diabetes Obes. Metab. 24, 1661-1666 (2022)
14.
Kiefer, L.S.* et al.: Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls. Diabetes Obes. Metab. 23, 1868–1878 (2021)
15.
Sachs, S. et al.: Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. Diabetes Obes. Metab. 23, 195-207 (2021)
16.
Seufert, J.* et al.: Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety. Diabetes Obes. Metab., DOI: 10.1111/dom.14549 (2021)
17.
Mathieu, C.* et al.: Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index >= 27 kg/m(2). Diabetes Obes. Metab. 22, 2151-2160 (2020)
18.
Pfohl, M.* et al.: Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting. Diabetes Obes. Metab. 22, 759-766 (2020)
19.
Brede, S.* et al.: Intranasal oxytocin fails to acutely improve glucose metabolism in obese men. Diabetes Obes. Metab. 21, 424-428 (2019)
20.
Jendle, J.* et al.: Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. Diabetes Obes. Metab., DOI: 10.1111/dom.13816 (2019)
▮◀ ◀◀ 1 ... 2 ... ▶▶ ▶▮